# Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors

> **NCT04659603** · PHASE2 · TERMINATED · sponsor: **Sanofi** · enrollment: 50 (actual)

## Conditions studied

- Breast Cancer Metastatic
- Pancreatic Carcinoma Metastatic

## Interventions

- **DRUG:** tusamitamab ravtansine
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT04659603
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-29
- **Primary completion:** 2024-02-16
- **Final completion:** 2025-01-19
- **Target enrollment:** 50 (ACTUAL)
- **Why stopped:** Sponsor decision, the decision is not related to any safety concern.
- **Last updated:** 2025-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04659603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04659603, "Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04659603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*